Table 2.
Groups of animals used in animal study.
| Group | Purpose of Experiment | Number of Animals | Cancer Induction | Administered Compound | Dose of Administered Compound | Route of Drug Administration |
|---|---|---|---|---|---|---|
| 1 | Biodistribution assessment | 6 | − | CSA-131 (800CW) | 10 µg/mL (including 1 µg/mL of IRDye® 800CW) |
intravenously |
| 2 | 6 | AuP@CSA-131 (800CW) | 10 µg/mL (including 1 µg/mL of IRDye® 800CW) |
|||
| 3 | 6 | IRDye® 800CW | 1 µg/mL | |||
| 4 | 6 | + | CSA-131 (800CW) | 10 µg/mL (including 1 µg/mL of IRDye® 800CW) |
||
| 5 | 6 | AuP@CSA-131 (800CW) | 10 µg/mL (including 1 µg/mL of IRDye® 800CW) |
|||
| 6 | 6 | IRDye® 800CW | 1 µg/mL | |||
| 7 | Anti-tumor efficiency evaluation | 3 | − | 0.9% sterile saline | 50 µL | intravenously |
| 8 | 3 | − | 0.9% sterile saline | 50 µL | intratumorally | |
| 9 | 3 | + | 0.9% sterile saline | 50 µL | intravenously | |
| 10 | 3 | + | 0.9% sterile saline | 50 µL | intratumorally | |
| 11 | 6 | + | CSA-131 | 10 µg/mL (50 µL) | intravenously | |
| 12 | 6 | + | AuP@CSA-131 | 10 µg/mL (50 µL) | ||
| 13 | 6 | + | CSA-131 | 10 µg/mL (50 µL) | intratumorally | |
| 14 | 6 | + | AuP@CSA-131 | 10 µg/mL (50 µL) |